Skip to main content
Loading

Intrepid Labs

Tuesday, February 27, 2024
Uris
Platform for Therapeutics
At Intrepid Labs, we're pioneering the future of drug development through advanced AI, robotics, and drug formulation science. Our mission is to enhance patient care by making treatments more personalized, effective, and accessible, while revolutionizing the way our customers and partners bring drugs to market. We achieve this by significantly reducing development time and costs, utilizing our innovative technology to identify optimal formulations rapidly and efficiently. For our investors, we create value through a diversified portfolio of low-risk, high-potential drug discovery assets. Our approach combines innovation with a cost-effective, risk-mitigated strategy, reflecting our commitment to excellence and transformative impact on the pharmaceutical industry. Driven by the belief in the power of our work, Intrepid Labs is setting new standards in drug development, delivering significant value across the healthcare ecosystem, and paving the way for a healthier future.
Speakers
Christine Allen, CEO and Cofounder - Intrepid

State

Ontario

Country

Canada

Website

https://intrepidlabs.tech/

CEO/Top Company Official

Christine Allen, Ph.D.

Lead Product in Development

VALIANT is a suite of software and hardware components which enables full autonomous machine learning guided optimization of drug formulations. Intrepid deploys VALIANT to develop new drug products for customers, partners and its internal portfolio.

Development Phase of Primary Product

Pre-Clinical
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Media Partner


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP